David Abasiwani Alagpulinsa, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Chemokine CXCL12 | 4 | 2023 | 464 | 1.350 |
Why?
|
Islets of Langerhans Transplantation | 4 | 2023 | 744 | 1.300 |
Why?
|
Alginates | 3 | 2023 | 252 | 0.840 |
Why?
|
Insulin-Secreting Cells | 2 | 2019 | 891 | 0.780 |
Why?
|
Multiple Myeloma | 4 | 2020 | 5180 | 0.710 |
Why?
|
Ubiquitin-Conjugating Enzymes | 1 | 2019 | 195 | 0.660 |
Why?
|
Islets of Langerhans | 2 | 2023 | 1350 | 0.660 |
Why?
|
Genomic Instability | 1 | 2020 | 695 | 0.540 |
Why?
|
Pyridinium Compounds | 1 | 2015 | 84 | 0.540 |
Why?
|
Peptide Nucleic Acids | 1 | 2015 | 25 | 0.520 |
Why?
|
Rad51 Recombinase | 1 | 2015 | 189 | 0.500 |
Why?
|
Ubiquitin | 1 | 2019 | 852 | 0.490 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2019 | 3336 | 0.480 |
Why?
|
Melphalan | 1 | 2015 | 431 | 0.460 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 2019 | 1121 | 0.430 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2015 | 671 | 0.420 |
Why?
|
Benzimidazoles | 1 | 2015 | 851 | 0.370 |
Why?
|
Hematologic Neoplasms | 1 | 2022 | 1831 | 0.360 |
Why?
|
Graft Survival | 2 | 2023 | 3740 | 0.350 |
Why?
|
Stem Cells | 2 | 2021 | 3567 | 0.350 |
Why?
|
Primates | 2 | 2023 | 544 | 0.210 |
Why?
|
Capsules | 1 | 2021 | 197 | 0.200 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 5169 | 0.180 |
Why?
|
Receptors, CXCR | 1 | 2018 | 52 | 0.160 |
Why?
|
Arthritis, Experimental | 1 | 2020 | 291 | 0.160 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2015 | 3557 | 0.150 |
Why?
|
Indolizines | 1 | 2015 | 37 | 0.140 |
Why?
|
Cyclic N-Oxides | 1 | 2015 | 78 | 0.140 |
Why?
|
Insulin | 2 | 2021 | 6583 | 0.130 |
Why?
|
S Phase | 1 | 2015 | 423 | 0.120 |
Why?
|
Animals | 8 | 2023 | 168788 | 0.120 |
Why?
|
Hematopoiesis | 1 | 2022 | 2069 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 13668 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2022 | 2072 | 0.100 |
Why?
|
Drug Synergism | 1 | 2015 | 1791 | 0.100 |
Why?
|
Genes, BRCA1 | 1 | 2015 | 781 | 0.100 |
Why?
|
Mice, SCID | 1 | 2015 | 2716 | 0.090 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3385 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2015 | 8426 | 0.090 |
Why?
|
Cell Line, Tumor | 2 | 2015 | 16687 | 0.080 |
Why?
|
Heart Failure | 2 | 2022 | 10905 | 0.080 |
Why?
|
HIV Infections | 2 | 2022 | 16718 | 0.070 |
Why?
|
Humans | 10 | 2022 | 744220 | 0.070 |
Why?
|
Cell Survival | 1 | 2015 | 5881 | 0.070 |
Why?
|
Mice | 3 | 2019 | 81178 | 0.070 |
Why?
|
DNA Damage | 1 | 2015 | 2432 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3712 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5755 | 0.060 |
Why?
|
Blood Glucose | 1 | 2019 | 6259 | 0.060 |
Why?
|
Monocytes | 2 | 2022 | 2594 | 0.060 |
Why?
|
Diterpenes, Kaurane | 1 | 2020 | 7 | 0.050 |
Why?
|
Osteopontin | 1 | 2022 | 296 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2015 | 7723 | 0.050 |
Why?
|
Mice, Inbred C57BL | 1 | 2019 | 21824 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2022 | 669 | 0.040 |
Why?
|
Mutation | 1 | 2022 | 29784 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18027 | 0.030 |
Why?
|
Fibrosis | 1 | 2022 | 2029 | 0.030 |
Why?
|
Lipoproteins | 1 | 2020 | 878 | 0.030 |
Why?
|
Transplantation, Heterologous | 1 | 2023 | 2382 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23404 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 11493 | 0.030 |
Why?
|
Swine | 1 | 2023 | 5940 | 0.030 |
Why?
|
Pilot Projects | 1 | 2023 | 8321 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3669 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5008 | 0.020 |
Why?
|
Heart | 1 | 2022 | 4465 | 0.020 |
Why?
|
Female | 3 | 2022 | 380197 | 0.020 |
Why?
|
Rats | 1 | 2020 | 24273 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 25043 | 0.010 |
Why?
|
Prospective Studies | 1 | 2022 | 53280 | 0.010 |
Why?
|